Rajendiran Sakshaleni, Veloo Yuvaneswary, Thahir Syahidiah Syed Abu, Shaharudin Rafiza
Environmental Health Research Centre, Institute for Medical Research (IMR), Ministry of Health, 40170 Shah Alam, Malaysia.
Antibiotics (Basel). 2022 Aug 18;11(8):1118. doi: 10.3390/antibiotics11081118.
Multidrug resistant (MDR) enterococci pose significant public health challenges. However, the extent of resistance in the environment is less explored. This study aimed to determine the antibiotic resistance in a poultry farm environment. Eighty enterococcal isolates recovered from the soil and effluent water of 28 poultry farms in Selangor state were included in the study for further bacterial identification and antibiotic susceptibility testing using a VITEK 2 system. Data were analyzed using Statistical Package for Social Science (SPSS) version 27. The resistance rate and MDR of enterococcal isolates were reported. Out of 80 isolates recovered, 72 (90%) exhibited resistance to at least one antibiotic, with 50 isolates (62.5%) being found to be MDR. All linezolid-resistant enterococci (LRE) exhibit MDR, which constituted 40% of resistance among all the isolates recovered from poultry environment. Since linezolid is listed as critically important antibiotics for clinical use by the World Health Organization (WHO), the higher resistance towards it and other critically important antibiotic for human use is a serious concern. Hence, relevant agencies need to investigate the use of clinically important antimicrobials in poultry farms paying special attention towards linezolid or any other antibiotics that can facilitate the development of LRE.
耐多药(MDR)肠球菌对公共卫生构成了重大挑战。然而,环境中耐药性的程度尚鲜有人探究。本研究旨在确定家禽养殖场环境中的抗生素耐药性。从雪兰莪州28个家禽养殖场的土壤和废水中分离出80株肠球菌,纳入本研究以使用VITEK 2系统进行进一步的细菌鉴定和抗生素敏感性测试。使用社会科学统计软件包(SPSS)27版对数据进行分析。报告了肠球菌分离株的耐药率和耐多药情况。在回收的80株分离株中,72株(90%)对至少一种抗生素表现出耐药性,其中50株(62.5%)被发现为耐多药。所有耐利奈唑胺肠球菌(LRE)均表现出耐多药,在从家禽环境中回收的所有分离株中,耐利奈唑胺肠球菌占耐药性的40%。由于利奈唑胺被世界卫生组织(WHO)列为临床使用的至关重要的抗生素,对其及其他对人类使用至关重要的抗生素的较高耐药性令人严重担忧。因此,相关机构需要调查家禽养殖场中临床重要抗菌药物的使用情况,特别关注利奈唑胺或任何其他可促进耐利奈唑胺肠球菌产生的抗生素。